The global antimicrobial therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to create a boom in the market includes the rising prevalence of deadly diseases such as HIV and HPV, which has created the need for high-quality diagnostics, that will make it possible to detect the infection early. After the diagnosis, the diagnosis, the demand for antimicrobial therapy will accelerate that destroys micro-organisms such as bacteria, fungi, or protozoans, or inhibits their growth. Microbiocidal therapies and treatments that inhibit the growth of micro-organisms or kill the micro-organisms are called microbiocidal therapies. A significant increase in antimicrobial resistance coupled with inadequate innovation in antibiotics has led to an increased interest in the development of alternative therapies to fight against bacterial infections.

Together with recent drug approvals, the existence of a strong pipeline will fuel antimicrobial therapeutics market growth. In December 2021, The Centers for Disease Control and Prevention (CDC) announced that it has awarded $22 million to nearly 30 organizations across the globe to combat antimicrobial resistance (AR) and other healthcare threats through the establishment of two new networks-; the Global Action in Healthcare Network (GAIHN) and the Global AR Laboratory and Response Network (Global AR Lab & Response Network).

These two new networks, paired with additional short-term research projects, will span more than 50 countries worldwide and build programs that focus on preventing infections in health care through proven infection control; build laboratory capacity to detect antimicrobial-resistant organisms in healthcare, the community, and environment; and develop new and innovative ways to more rapidly detect and respond to threats like AR and COVID-19.

The global antimicrobial therapeutics market analysis includes some of the key market players such as GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc., and Sanofi, among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. In July 2020, more than 20 leading biopharmaceutical companies are announcing the launch of the AMR (Antimicrobial Resistance) Action Fund that will invest in developing innovative antibacterial treatments. The Fund aims to bring 2-4 new treatments to patients by 2030. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc., and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antimicrobial Therapeutics Market Report Segmentation

By Type

• Antifungals

• Antivirals

• Antibiotics

• Antiparasitic

By Application

• Skin Infections

• Respiratory Infections

• Gastrointestinal Infections

• Other Infections

By Administration

• Oral

• Intravenous

Global Antimicrobial Therapeutics Market by Region